Ardena Completes Divestment of Swedish API Manufacturing Site to Nanologica
核心洞察
Ardena (搜索) has completed the sale of its Södertälje drug substance manufacturing facility in Sweden to Nanologica AB (搜索), with the site reverting to its original name Syntagon AB (搜索).
The facility employs more than 45 people and specializes in small molecule active pharmaceutical ingredients, supporting programs from early development through commercial manufacturing.
As part of the transaction, Ardena (搜索) becomes a shareholder in Nanologica and will maintain an ongoing services agreement to ensure continuity for existing customer programs.
Ardena (搜索), a specialist contract development and manufacturing organization (CDMO) and bioanalytical contract research organization (CRO), announced on January 29, 2026, the completion of its divestment of the drug substance manufacturing site in Södertälje, Sweden, to Nanologica AB (搜索). The facility will operate as a wholly owned subsidiary within the Nanologica Group under its original name, Syntagon AB (搜索).
Strategic Transaction Details
The Södertälje facility represents a well-established drug substance CDMO with more than 45 employees and a proven track record in small molecule active pharmaceutical ingredients (APIs). The site supports pharmaceutical programs across the entire development spectrum, from early development through clinical supply to commercial manufacturing. Recent years have seen significant investments in chromatographic purification and falling film distillation capabilities, enhancing the facility's technical capabilities.
Under the agreement terms, Ardena (搜索) will become a shareholder in Nanologica, while Jeremie Trochu, CEO of Ardena, will join Nanologica's Board of Directors. This arrangement reflects the long-standing relationship between the two companies and ensures strategic alignment moving forward.
Operational Continuity and Future Collaboration
To maintain seamless operations for existing programs, Ardena (搜索) will remain a customer through an ongoing services agreement. This arrangement ensures continuity for current customer programs while both companies plan to collaborate on new customer projects where relevant.
"This transaction supports Ardena (搜索)'s strategy to focus investment and growth on specialized capabilities that enable precision medicines and deliver meaningful patient impact across drug product, nanomedicine, drug conjugates, biomarkers and bioanalysis," commented Jeremie Trochu, CEO of Ardena. "At the same time, it reflects our commitment to ensuring the best long-term future for the Södertälje site and its talented team."
Strategic Focus Realignment
The divestment aligns with Ardena (搜索)'s strategic repositioning to concentrate on specialized capabilities that enable precision medicines. The company will continue supporting customers with an integrated approach to development and manufacturing, facilitating efficient progress from early development through clinical and commercial stages for complex therapies.
Trochu expressed confidence in Nanologica as the acquiring company, stating, "Nanologica is a partner we know well and is ideally positioned to build on the strong foundation in Södertälje and offer an exciting future for the site. I'm pleased to partner with Andreas and the entire Nanologica team, and I look forward to joining their Board of Directors."
About the Companies
Nanologica AB (搜索) is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical companies. The company's silica-based products are specifically developed for the purification of peptide drugs, including insulin and GLP-1 analogues (搜索), designed to support efficient and long-lasting purification processes. Nanologica is headquartered in Södertälje, Sweden, with shares listed on Nasdaq Stockholm Main Market.
Ardena (搜索) specializes in pharmaceutical contract development and manufacturing services, focusing on precision medicines and complex therapies. The company's integrated solutions enable innovative and complex molecules through services in nanomedicine and drug conjugates, advanced drug product development and manufacturing, solid-state chemistry, bioanalytical services, and CMC regulatory support.
The transaction was completed following satisfaction of customary closing conditions.